相约AACR丨拿因生物受邀参加壁报展示 2026/04/20 2 P.M.-5 P.M.PDT
中国杭州，2026年2月5日——致力于破解肿瘤耐药难题的全球领先生物医药企业拿因生物今日宣布，其自主研发的全球首创靶向内质网应激（ER stress）通路的小分子调节剂取得重要进展，相关成果将于2026年4月17-22日在美国加利福尼亚州圣地亚哥举行的美国癌症研究协会（AACR）年会上以壁报形式重磅亮相。该突破性研究为选择性诱导STK11/TP53缺陷型肿瘤细胞发生调节性细胞死亡提供了全新靶点和治疗策略，有望解决此类肿瘤耐药复发的关键问题。
【研究亮点速览】
壁报主题：A first-in-class ER stress modulator selectively induces regulated cell death of STK11/TP53-deficient cancer cells（全球首创内质网应激调节剂——选择性诱导STK11/TP53缺失肿瘤细胞调节性细胞死亡）
会议板块：实验与分子治疗（Experimental and Molecular Therapeutics）
专题研讨：新型治疗药物与靶点2（Novel Therapeutics and Drug Targets 2）
展示时间：2026年4月20日14:00-17:00（太平洋时间）
学术坐标：16号展区2号壁报（摘要编号：3074）
作为全球肿瘤学领域的权威学术盛会，AACR年会历来是检验创新药物研发实力的试金石。此次研究成果的入选，不仅印证了拿因生物在肿瘤耐药领域的突破性源头创新能力，更凸显了该候选药物在精准靶向治疗策略上的临床转化潜力。公司研发团队通过精准调控内质网应激通路，为攻克STK11/TP53缺陷型肿瘤的耐药难题开辟了全新路径。
关于拿因生物
拿因生物于2020年12月正式成立，其科学家团队从全新药靶等生物学源头开启探索，运用基于协同致死的联合治疗等前沿策略，全力攻克肿瘤耐药复发等关键瓶颈问题，积极研发肿瘤干细胞分化诱导剂和调节性细胞死亡诱导剂等创新药物。拿因生物始终以满足未被满足的临床需求为使命，期望为广大患者带来显著的临床获益。
Nain Biotech to Present Preclinical Data on a First-in-Class ER Stress Modulator at AACR 2026
Hangzhou, China, February 5, 2026 - Nain Biotech, a global first-in-class drug discovery company dedicated to addressing cancer drug resistance, today announced that it will present a poster featuring preclinical results of its first-in-class small molecule ER stress modulator at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Details of the poster presentation are as follows:
Poster Title: A first-in-class ER stress modulator selectively induces regulated cell death of STK11/TP53-deficient cancer cells
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Therapeutics and Drug Targets 2
Session Start: 4/20/2026 2:00:00 PM
Session End: 4/20/2026 5:00:00 PM
Location: Poster Section 16
Poster Board Number: 2
Published Abstract Number: 3074
The AACR Annual Meeting 2026, a premier global oncology conference to be held from April 17 to 22 in San Diego, California, serves as a definitive benchmark for innovative cancer research. The acceptance of Nain's poster at this meeting points to the therapeutic potential of its approach: selectively targeting the ER stress pathway to induce regulated cell death in STK11/TP53-deficient tumors.
About Nain Biotech
Nain Biotech was founded in December 2020. Nain focuses on developing novel CSC and RCD modulators, finding novel drug targets, and tackling drug resistance in cancer. Nain's team of scientists, by targeting drug resistance for cancer eradication, are hoping to bring significant clinical benefits to patients and committed to addressing unmet clinical needs.
